Last reviewed · How we verify
Ropivacaine 10%
At a glance
| Generic name | Ropivacaine 10% |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
- Preop US-Guided Nerve Blocks for Pain & Recovery After Ankle Arthroscopy (NA)
- SPSIP Block vs SAP Block for Post-VATS Pain (NA)
- Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block (NA)
- Intrapleural Ropivacaine Infusion in Cardiac Surgery (PHASE4)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 10% CI brief — competitive landscape report
- Ropivacaine 10% updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI